Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Cash from Investing Activities (2021 - 2025)

Historic Cash from Investing Activities for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to $15.7 million.

  • Kezar Life Sciences' Cash from Investing Activities fell 3469.66% to $15.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.6 million, marking a year-over-year decrease of 2361.23%. This contributed to the annual value of $80.4 million for FY2024, which is 576.23% up from last year.
  • Per Kezar Life Sciences' latest filing, its Cash from Investing Activities stood at $15.7 million for Q3 2025, which was down 3469.66% from $11.4 million recorded in Q2 2025.
  • In the past 5 years, Kezar Life Sciences' Cash from Investing Activities ranged from a high of $38.5 million in Q3 2021 and a low of -$82.5 million during Q4 2021
  • For the 5-year period, Kezar Life Sciences' Cash from Investing Activities averaged around $4.1 million, with its median value being $13.7 million (2025).
  • In the last 5 years, Kezar Life Sciences' Cash from Investing Activities crashed by 856564.77% in 2022 and then skyrocketed by 77437.09% in 2023.
  • Over the past 5 years, Kezar Life Sciences' Cash from Investing Activities (Quarter) stood at -$82.5 million in 2021, then skyrocketed by 89.5% to -$8.7 million in 2022, then soared by 421.88% to $27.9 million in 2023, then dropped by 14.83% to $23.7 million in 2024, then crashed by 33.83% to $15.7 million in 2025.
  • Its Cash from Investing Activities was $15.7 million in Q3 2025, compared to $11.4 million in Q2 2025 and $13.7 million in Q1 2025.